Since 2016, Food and Drug Administration (FDA) has approved several programmed cell death 1 (PD1)/PD1 ligand 1 (PD-L1) inhibitors for the clinical treatment of urothelial bladder cancer (BLCA), particularly for patients in advanced stages, who have a median overall survival (OS) duration of 14.0 months and a 5‐year survival of 13%2. The gene discussed is PDCD1; the disease is bladder transitional cell carcinoma.